{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T05:04:51Z","timestamp":1789362291944,"version":"build-2803163510"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Residual synovial inflammation may persist in patients with rheumatoid arthritis (RA) despite clinical remission or low disease activity. Conventional inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) may not adequately reflect subclinical synovitis detected by musculoskeletal ultrasound. Ferritin, an acute-phase reactant involved in inflammatory signaling, may represent a complementary biomarker of ongoing synovial inflammation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the association between serum ferritin levels and Power Doppler (PD)-detected synovitis in patients with RA who were in clinical remission or low disease activity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, single-center, cross-sectional study, 188 individuals were enrolled, including 132 patients with RA receiving either conventional synthetic disease-modifying antirheumatic drugs or adalimumab therapy and 56 healthy controls. All patients with RA fulfilled the 2010 ACR\/EULAR classification criteria and had DAS28-ESR scores &amp;lt;3.2. Musculoskeletal ultrasound was performed in all patients with RA, and PD positivity was defined as a patient-level PD score of \u22651. Ferritin was analyzed as both a continuous and a categorical variable. To account for potential data separation and model overfitting, Firth's penalized likelihood multivariable logistic regression models were constructed, including adjustments for baseline iron status (serum iron and hemoglobin). Receiver operating characteristic (ROC) analysis was used to assess diagnostic performance, validated internally via 1,000 bootstrap resamples, and compared against CRP and ESR using DeLong tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      PD positivity was identified in 40 of 132 patients with RA (30.3%). Ferritin levels were significantly higher in PD-positive than in PD-negative patients (median 117.0 vs. 17.0\u2005ng\/mL,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), whereas CRP (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.872) and ESR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.974) did not differ. In univariable Firth logistic regression, each 10\u2005ng\/mL increase in ferritin was associated with higher odds of PD positivity (Firth OR 2.49, 95% CI 1.70\u20133.66;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). In the multivariable model adjusted for age, sex, treatment group, CRP, and ESR, ferritin remained independently associated with PD positivity (adjusted Firth OR 2.51 per 10\u2005ng\/mL, 95% CI 1.66\u20133.79;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001), and this independence persisted after further adjustment for serum iron and hemoglobin (adjusted Firth OR 2.14, 95% CI 1.51\u20133.05;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). ROC analysis demonstrated excellent discriminatory performance for ferritin, with an optimism-corrected AUC of 0.985 (bootstrap 95% CI 0.968\u20130.997), which was significantly superior to CRP (AUC 0.509, DeLong\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) and ESR (AUC 0.498, DeLong\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001). An exploratory ferritin threshold of 70\u2005ng\/mL yielded 95.0% sensitivity (bootstrap 95% CI 86.7\u2013100.0%), 94.6% specificity (bootstrap 95% CI 89.1\u201398.9%), 88.4% positive predictive value (bootstrap 95% CI 77.8\u201397.4%), and 97.8% negative predictive value (bootstrap 95% CI 94.2\u2013100.0%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum ferritin was independently associated with ultrasound-detected synovial inflammation in patients with RA who were in clinical remission or low disease activity. In this cohort, ferritin showed higher discriminatory performance than CRP and ESR, supporting its potential role as a complementary biomarker of residual synovial inflammation. However, the proposed cutoff of 70\u2005ng\/mL must be regarded as exploratory, and independent external validation in longitudinal prospective cohorts is required before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1921362","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:35:57Z","timestamp":1789360557000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum ferritin as an independent biomarker of subclinical synovitis in rheumatoid arthritis patients in clinical remission or low disease activity"],"prefix":"10.3389","volume":"13","author":[{"given":"Duygu","family":"Kurtulus","sequence":"first","affiliation":[{"name":"Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Uskudar University, Memorial Ata\u015fehir Hospital","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adem","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Rheumatology, Faculty of Medicine, Necmettin Erbakan University","place":["Konya, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR Recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/art.42347","article-title":"American College of rheumatology\/EULAR remission criteria for rheumatoid arthritis: 2022 revision","volume":"75","author":"Studenic","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13075-021-02426-w","article-title":"Using a DAS28-CRP-steered treat-to-target strategy does not eliminate subclinical inflammation as assessed by ultrasonography in rheumatoid arthritis patients in longstanding clinical remission","volume":"23","author":"Terslev","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S277","DOI":"10.5152\/eurjrheum.2022.20224","article-title":"Ultrasound in the evaluation of rheumatoid arthritis","volume":"11","author":"De Agustin De Oro","year":"2024","journal-title":"Eur J Rheumatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"e004269","DOI":"10.1136\/rmdopen-2024-004269","article-title":"Persistence of power Doppler ultrasonography-detected synovitis over 1 year of follow-up predicts poor prognosis in rheumatoid arthritis in clinical remission: the SONORE prospective longitudinal study","volume":"10","author":"Mouterde","year":"2024","journal-title":"RMD Open"},{"key":"B6","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1093\/intimm\/dxx031","article-title":"Hyperferritinemia and inflammation","volume":"29","author":"Kernan","year":"2017","journal-title":"Int Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"37667","DOI":"10.56305\/001c.37667","article-title":"Update in hyperferritinemic syndromes: recognition and management\u2014a scoping review","volume":"1","author":"Vassilopoulos","year":"2022","journal-title":"Brown J Hosp Med"},{"key":"B8","first-page":"984","article-title":"Ultrasound detection of subclinical synovitis in rheumatoid arthritis patients in clinical remission: a new reduced-joint assessment in 3 target joints","volume":"36","author":"Picchianti Diamanti","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1002\/art.22190","article-title":"Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression","volume":"54","author":"Brown","year":"2006","journal-title":"Arthritis Rheum"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4590","DOI":"10.1093\/rheumatology\/keac261","article-title":"Musculoskeletal ultrasound for treating rheumatoid arthritis to target-a systematic literature review","volume":"61","author":"Silvagni","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/cei.13057","article-title":"H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome","volume":"191","author":"Ruscitti","year":"2018","journal-title":"Clin Exp Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.3899\/jrheum.160193","article-title":"Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission: a systematic review and metaanalysis.","volume":"43","author":"Han","year":"2016","journal-title":"J Rheumatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/art.33312","article-title":"Power doppler ultrasound, but not low-field magnetic resonance imaging, predicts relapse and radiographic disease progression in rheumatoid arthritis patients with low levels of disease activity","volume":"64","author":"Foltz","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B14","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/j.bbagen.2010.03.011","article-title":"Serum ferritin: past, present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1053\/j.sult.2010.11.004","article-title":"The role of ultrasound in rheumatology","volume":"32","author":"Iagnocco","year":"2011","journal-title":"Semin Ultrasound CT MR"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 Rheumatoid arthritis classification criteria: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheum"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e000428","DOI":"10.1136\/rmdopen-2016-000428","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-part 1: definition and development of a standardised, consensus-based scoring system","volume":"3","author":"D'Agostino","year":"2017","journal-title":"RMD Open"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e000427","DOI":"10.1136\/rmdopen-2016-000427","article-title":"Scoring ultrasound synovitis in rheumatoid arthritis: a EULAR-OMERACT ultrasound taskforce-part 2: reliability and application to multiple joints of a standardised consensus-based scoring system","volume":"3","author":"Terslev","year":"2017","journal-title":"RMD Open"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1921362\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T04:36:02Z","timestamp":1789360562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1921362\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":19,"alternative-id":["10.3389\/fmed.2026.1921362"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1921362","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"article-number":"1921362"}}